Critical Care Reviews Newsletter

Newsletter 552  |  July 21st 2022

Please support our work to share science

COCA Trial Result Livestream Flyer

Dr Neill Adhikari discusses the results of the LOVIT trial at CCR22

Welcome to the 552nd Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature for the week of July 4th to 10th.

The highlights of this week's edition are randomised controlled trials on oral sabizabulin for high-risk, hospitalized adults with Covid-19 & high-dose dexamethasone and oxygen support strategies in ICU patients with severe COVID-19 acute hypoxemic respiratory failure; systematic reviews and meta analyses on extravascular lung water & early low-calorie enteral nutrition support; and observational studies on fluid accumulation and major adverse kidney events in sepsis & management of pediatric shock in the post-fluid expansion as supportive therapy trial era.

There are also guidelines on temporary mechanical circulatory support in cardiogenic shock & hereditary angioedema; narrative reviews on electrical impedance tomography in ARDS & surviving sepsis campaign guidelines 2021; an editorial on resuscitation for moribund alpinists stranded at high altitudes; and commentaries on optimising aerosolized therapies & blood transfusion.

If you only have time to read one review article this week, try this one on identifying encephalopathies from acute metabolic derangements.

We've started to release the videos from CCR22. First up is the LOVIT trial, demonstrating harm from vitamin C in the management of sepsis.

You can now become a Supporter of CCR, where you can contribute as little as the price of a cup of coffee per month or make a one-off donation to assist us. All our content is freely available without the need to register. Help us share science for the benefit of all.

I hope you find this newsletter useful.


Until next week

Rob

 

Supported by

My Intensive Care Logo

 

 

 

 

Disseminating Evidence for over a Decade


© All rights reserved.

Back to Top